Deep Genomics is pioneering the integration of artificial intelligence (AI) with RNA biology to revolutionize drug development, particularly for genetic conditions. Their proprietary AI platform, BigRNA, is the first foundation model specifically designed for RNA therapeutics. This advanced model leverages extensive datasets and machine learning techniques to predict RNA expression at a sub-gene resolution, enabling the identification of novel biological mechanisms and therapeutic candidates. Unlike traditional AI models that focus on singular tasks, BigRNA is capable of performing a wide range of functions, including target identification, molecule-target interaction predictions, and the design of therapeutic candidates across various RNA modalities such as oligonucleotides and mRNA.

The capabilities of BigRNA extend beyond simple predictions, as it is engineered to discover complex genetic interactions and regulatory mechanisms that are often overlooked by conventional approaches. This positions Deep Genomics at the forefront of addressing a multitude of genetic conditions by programming RNA therapies that can precisely target the underlying genetic causes. The ongoing development of BigRNA+ aims to further enhance the platform's ability to tackle more intricate genetic diseases, thereby expanding the potential for innovative treatments in the realm of genetic medicine.

Canada

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies.

The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.

Deep Genomics

Company Details